Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, ...

首个专门针对清除潜伏HIV-1细胞的T细胞受体（TCR）疗法已经通过了初步临床试验。这种双特异性免疫疗法可以靶向并清除那些长期携带HIV的CD4+细胞，也就是所谓的“病毒储存库”。

Founded in 1999, TCR is today a major business-to-business service provider in the GSE sector. TCR implements the rental, repair and maintenance of Ground Support Equipment (GSE) and owns over 50,000 ...

MHH team aims to intervene in the autoimmune process and stop the destruction of insulin-producing beta cells in the pancreas ...

2024年下半年，国产TCE双抗交易风靡全球，而其中与自免相关交易更是占到了所有7笔国产TCE双抗交易中的5笔，堪称“最红”的国产创新药物类型（更具体分析详见《国产新药爆红》）。

1 Immunology Graduate Program, Baylor College of Medicine, Houston, TX, United States 2 Department of Pathology, University of Utah, Salt Lake City, UT, United States Introduction: Chimeric antigen ...